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The increased probability of recurrence and accelerated tumour
growth in the location of tissue injury are common clinical compli-
cations associated with the invasive procedures frequently used in
cancer therap y. The concept that injuries promote tumour develop-
ment at the injured site was suggested already in 1927 (Deelman,
1927). This concept was extended to show that trauma increased
the probability of tumour formation in the injured o rgan, without
affecting the distribution to other sites, by promoting implantation
and proliferation of circulating cancer cells (Murthy et al, 1991).
The tumours specifically developed in traumatized o rgans in the
injury site, and as the wounds heal their ability to facilitate implan-
tation and/or growth of tumour cells decreases (Murthy et al,
1989). It seems that the same repair processes involved in wound
healing also contribute to tumour attachment and growth (Dvorak
et al, 1995).  We showed previously that injured skin tissue
provides a favourable milieu for the neovascularization and
growth of C6 glioma spheroids, implanted subcutaneously in nude
mice (Abramovitch et al, 199 8a). Moreove r, we showed that the
presence of microtumours in an injured tissue inhibited the healing
process, leaving an open persistent wound. O’Reilly et al (1994,
1996) showed recently that excision of a primary tumour acceler-
ates the growth of a secondary tumour and metastases in other
organs. This acceleration of tumour growth has been attributed
to the removal of primary tumou r-generated inhibitory factors.
Howeve r, recent studies have shown that su rgical wounding of
normal tissues significantly stimulated the growth of malignant
tissues without the concomitant excision of a tumour mass
(Bogden et al, 1997). This humoral stimulating e ffect was not
histologically specific or species specific (Bogden et al, 1997).
The process of healing and repair of damaged tissue is highly
regulated by a la rge number of specific soluble growth factors
which are released within the wound environment and which
appear to induce neovascularization, inflammation, cell prolifera-
tion and deposition of collagen and other extracellular matrix
molecules within the wound. These events are stimulated and
regulated by mitogens and chemotactic factors which are secreted
from cells in the wound border and from inflammatory cells
(Lynch, 1991; Frank et al, 1995; Moulin, 1995). It appears that the
same mediators of cell growth and stromal synthesis are involved
in malignanc y, fetal growth and wound healing. Many growth
factors are released during tissue repai r, and some of them such as
fibroblast growth factors (FGFs), transforming growth facto r  a
(TGF-a), epidermal growth factor (EGF), platelet-derived growth
factor (PDGF), vascular endothelial growth factor (VEGF),
tumour necrosis facto r  a (TNF-a), TGF-band heparin-binding
epidermal growth facto r-like growth factor (HB-EGF) have been
shown to be angiogenic in vivo ( Lynch, 1991; Moulin, 1995;
Abramovitch et al, 1998b). In addition, many of these growth
factors are known to be directly mitogenic to tumour cells. It was
shown previously that EG F, PDGF-BB and other growth factors
affect glioma spheroids growth, migration and invasion (Pedersen
et al, 1994). An additional enhancing mechanism could be the
induction of VEGF secretion in the tumour as a result of exposure
to growth factors released from the wound. It was recently shown
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Summar yThe goal of this work was to determine the molecular basis for the induction of tumour vascularization and progression by injury.
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concentrations of EGF, PDGF-BB and basic fibroblast growth
factor (bFGF) (Tsai et al, 1995).
In light of the complexity of wound healing and the multiple cell
types and growth factors involved, it is of interest to determine
whether the stimulatory effects of injuries on tumour progression
can be attributed to a restricted repertoire of molecules whose
activity could possibly be antagonized.
The goal of this study was to identify the key growth factors that
are found in healing wounds and exert a major stimulatory effect
on tumour growth. In order to study the molecular basis for this
stimulatory effect, we developed an experimental model using
wound fluid derived from a cutaneous wound in pig (Marikovsky
et al, 1993) and injected locally to an implanted C6 glioma
spheroid. Using this system, we could reproduce the stimulatory
effects of the wound on tumour progression, and could analyse the
active constituents present in the wound. We show here that wound
fluid collected during the first 3 days of pig injury enhances
tumour growth in vivo, that wound fluid is angiogenic in vivo and
mitogenic to bovine endothelial cells in vitro, and that wound fluid
is directly mitogenic to C6 glioma cells. HB-EGF and PDGF were
previously shown to be the major heparin-binding growth factors
present in wound fluid (Marikovsky et al, 1993). Moreover, we
have recently demonstrated that HB-EGF is angiogenic in vivo
and induces VEGF expression in vascular smooth muscle cells
(Abramovitch et al, 1998b). Here, we demonstrate that in wound
fluid HB-EGF and PDGF are the major mitogens for C6 glioma
cells.
MATERIALS AND METHODS
Materials
Human PDGF-BB and neutralizing anti-human PDGF antibodies
were purchased from Collaborative Biomedical Products
(Bedford, MA, USA). Recombinant HB-EGF and neutralizing
anti-human HB-EGF polyclonal antibody 197 were kindly
provided by Dr Judith A Abraham (Scios Nova, Mountain View,
CA, USA). Neutralizing anti-HB-EGF polyclonal antibody 197
was raised in goats, directed against recombinant 77-amino-acid
human HB-EGF. Antibodies were incubated with the wound fluid
for 16 h (20 mg ml–1, 4°C) and then added to cells. The antibodies
are specific and do not interact with either EGF, TGF-a or
amphiregulin. Pig plasma (Sigma) was used as a control for the
effect of wound fluid.
Cell culture and spheroid preparation
C6 rat glioma cells were routinely cultured in DMEM (Dulbecco’s
modified Eagle medium) supplemented with 5% fetal calf serum
(FCS, Biological Industries, Israel), penicillin (50 unit ml–1),
streptomycin (50 mg ml–1) and fungizone (125 mg ml–1) (Biolab).
Aggregation of cells into small spheroids of about 150 mm was
initiated in agar-coated bacteriological plates. After 4–5 days in
culture, the spheroid suspension was transferred to a 250-ml
spinner flask (Bellco, USA) and the medium changed every other
day for approximately 6 weeks. Other parameters of spheroid
culture were as reported previously (Abramovitch et al, 1995,
1998c).
Spheroid growth kinetics
Spheroids used for growth measurements were cultured indi-
vidually in 24-well plates (Nunc, Denmark) coated with agar. An
overlay suspension of 0.5 ml DMEM with the corresponding
growth factor (1 ng ml–1) was added. Spheroid diameter was
measured daily using a microscope with a calibrated reticle in the
eyepiece. The spheroid volume was calculated from the diameter
measurements (four spheroids per treatment).
Spheroid implantation in nude mice
Male CD1-nude mice (2 months old, 30 g body weight) were
anaesthetized with a single dose of 75 mg g–1 ketamine plus
3 mg g–1 xylazine (i.p.) and placed in a sterile laminar flow hood.
A single spheroid per mouse (approximately 1 mm in diameter)
was implanted subcutaneously in the lower back through a 4-mm
incision as reported previously (Abramovitch et al, 1995). The
incision was formed by fine surgical scissors and closed with
cyanoacrylate (Super Glue-3, Loctite, Ireland).
Wound fluid preparation
Wound fluid (WF) was derived from injured pigs at various days
after injury as reported previously (Marikovsky et al, 1993).
Briefly, medium partial-thickness excisional wounds (15 ´ 15 ´
1.2 mm) were created on the back of female Large White ´
Landraei pigs (40 kg). Each wound was covered with a liquid-tight
vinyl chamber filled with 1.2 ml of normal saline containing
penicillin (100 units ml–1) and streptomycin sulphate (100 mg ml–1).
The solution from all wounds was pooled daily after injury,
centrifuged, filtered through 0.45-mm filters and frozen at –20°C.
Control solutions consisted of saline, penicillin (100 units ml–1)
and streptomycin sulphate (100 mg ml–1).
Wound fluid injections to tumour-bearing mice
WF derived from injured pigs (first 2 days after injury) was
injected in mice in which a spheroid was implanted more than
1 cm away from the incision (subcutaneous injections began with
spheroid implantation and continued every 2–3 days, close to the
implanted spheroid). Control animals were injected with saline or
with phosphate-buffered saline (PBS) supplemented with anti-
biotics or with pig plasma.
Analysis of the angiogenic activity of wound fluid
Spherical agarose beads of approximately 1 mm in diameter were
formed from 4% low gelling temperature agarose (Sigma) with
either phosphate-buffered saline (PBS) or basic fibroblast growth
factor (b-FGF; 0.5 or 5 mg), pig plasma or WF (fourfold concen-
trated). The tested compounds (5 ml per bead) were warmed to
38°C by placing them for a few seconds in sterile micro test tubes
in a dry bath. Agarose solution (6% in saline, 45°C) was then
added (10 ml per bead), and beads were formed above ice using a
20-ml pipette tip. Beads were implanted in nude mice 1 cm from
the incision site, one bead per mouse. All control beads contained
antibiotics as in the wound fluid (penicillin, 100 units ml–1 and
streptomycin sulphate, 100 mg ml–1).
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Magnetic resonance imaging (MRI) of the implanted
spheroids or beads
MRI experiments were performed on a horizontal 4.7 T Bruker-
Biospec spectrometer using a 2-cm surface coil. Mice were anaes-
thetized with a single dose of 75 mg g–1 ketamine plus 3 mg g–1
xylazine (i.p.), and placed supine with the tumour located at the
centre of the surface coil. Gradient echo images (slice thickness of
0.5–0.6 mm, TR 100 ms, 256 ´ 256 pixels, in plane resolution of
110 mm) were acquired with echo time of 20 ms. Growth of the
capillary bed was reflected by reduction of the mean intensity at a
region of interest of 1 mm surrounding the spheroid or the
agarose bead (Abramovitch et al, 1995, 1998a,c; Schiffenbauer
et al, 1997). Data is reported here as the apparent vessel density
[AVDMRI = – ln S(a)/S(0)], in which S(a) is the mean intensity at a
region of interest of 1 mm surrounding the spheroid or the agarose
bead and S(0) is the mean intensity of a distant muscle. Angiogenic
capacity of the implanted beads was evaluated from the difference
between AVDMRI on day 4 and AVDMRI on day 1 after implantation:
DAV D= AVDMRI(day 4) – AVDMRI(day 1)
Tumour volume was determined from two orthogonal sets of
multislice gradient echo images covering the entire tumour, as
reported previously (Abramovitch et al, 1995, 1998a).
MRI data was analysed on a Personal Iris work station (Silicon
Graphics, USA) with software from NMRi (Tripos). Statistical
significance of treatments was determined using Student’s t-test or
ANOVA. Errors reported are the standard deviation.
Measurement of DNA synthesis
C6 rat glioma cells were plated in 96-well plates (Nunc, Denmark)
(5000 cells per well) in DMEM with 5% FCS. After 6 h, the cells
were rinsed and incubated for 48 h in serum-free medium. Wound
fluid, pig plasma or growth factors were then added for 24 h
(triplicates). [3H]thymidine 5 mCi ml–1 (Rotem Industries, Israel)
was added to the cells for the last 14 h (10 ml). The cells were
rinsed with 100 ml methanol for 10 min, followed by 200 ml 5%
cold trichloroacetic acid. Afterwards, cells were washed with
water and lysed with 150 ml 0.5 M sodium hydroxide. Radioactive
thymidine incorporation into DNA was determined for 60 s
with 3 ml scintillation liquid (Ultima Gold, Packard) in a liquid
scintillation b-counter.
Brain bovine capillary endothelial cells (BBCE) were plated in
24-well plates (6000 cells per well) in 500 ml medium [low
glucose DMEM (1 g l–1) +10% Colorado calf serum (CS) (Gibco,
USA) and antibiotics: penicillin (100 units ml–1), streptomycin
(100 mg ml–1), 2 mM glutamine (Biolab, Israel) (PSG).
After 24 h, the medium was changed to serum starvation
medium (2% CS, 0.5% BSA, and PSG) for 24 h in the presence of
wound fluid or wound fluid-derived growth factors. [3H]thymidine
(0.6 mCi) was added for the last 6 h. DNA synthesis assays
(duplicates) were performed as described above.
All values were scaled by the counts from the respective control
samples that were exposed to serum starvation medium alone.
Histology
Skin with tumour specimens were fixed in neutral buffer formalde-
hyde (pH = 7) for 24 h, washed in 70% ethanol, embedded in
paraffin, sectioned and stained with light green (Masson), eosin
and haematoxylin.
RESULTS
Exogenous wound fluid promotes tumour
neovascularization and growth
The stimulatory effects of wounds on tumour growth are clearly
evident for in situ wounds on C6 glioma tumours implanted in
nude mice (Abramovitch et al, 1998a). Unfortunately, the minute
amounts of growth factors released in these in situ wounds do not
allow for molecular analysis of the role of the different growth
factors. To elucidate this point, we resorted to a more complex
experimental system. The stimulatory effect of the wound on
tumour progression was studied here using wound fluid (WF)
derived from a pig wound model. The first step in this project was
to test whether WF stimulated vascularization of implanted spher-
oids and accelerated tumour growth, as observed previously for in
situ dermal incisions (Abramovitch et al, 1998a). Wound fluid was
derived from partial thickness excisional wounds created on the
back of a pig as reported previously (Marikovsky et al, 1993), and
was injected subcutaneously next to an implanted C6 glioma
spheroid (Figure 1). Control mice were injected with PBS (n =9 )
or with pig plasma (n = 2). Wound fluid administration was initiated
AB
Figure 1 Wound fluid enhances tumour growth for C6 glioma spheroids implanted in nude mice. (A and B) Histological sections of C6 glioma tumours 21 days
after implantation (bar, 0.1 cm). Mice were injected with a total amount of 2.4 ml of either wound fluid derived from day 2 of pig injury (A) or PBS (B);
subcutaneous injections, close to the implanted spheroid, eight injections of 300 ml each every 2–3 days starting on the day of spheroid implantation. Tumour
treated with wound fluid showed a significant effect through the entire experiment and tumour volume was fourfold larger at the end of the experiment. Inserts,
photographs of the same tumours as in A and B (bar, 0.5 cm)Analysis of tumour growth enhancement by injury 1395
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at the time of spheroid implantation. Care was taken to position the
spheroid at a distance larger than 1 cm from the incision so as to
avoid direct stimulation of tumour growth by the in situ surgical
wound (Abramovitch et al, 1998a).
As observed previously for spheroids implanted on a full thick-
ness dermal incision, treatment with WF reduced the lag in tumour
growth (from 5 days to 3 days; n = 5), and the early stages of
neovascularization were enhanced (vascular density was maximal
on day 4, relative to day 6 for control spheroids; n = 5). In contrast
to wound fluid, pig plasma and PBS did not induce tumour
growth. The apparent vessel density (AVDMRI) was derived from
gradient echo images of tumour treated with WF (6 injections, 100
ml each, every 48 h) 8 days after implantation. Vessel density was
much larger in WF-treated spheroids than that observed in control
spheroids (0.964 ±0.19, n = 5, and 0.447 ±0.19, n = 8, respectively;
P = 0.0003). Histological sections show that the enhanced rate of
tumour growth can be attributed to the tumour cells themselves
and not to infiltrating host cells such as fibroblasts (Figure 1).
In addition to the proangiogenic activity, WF also accelerated
the rate of tumour growth. Tumour growth in WF-treated mice
was monitored by MRI and was compared with the rate of tumour
growth in control mice. For mice that were injected with a total
amount of 0.4 ml wound fluid (four injections of 100 ml WF each,
every 2–3 days, n = 3), the effect on tumour growth rate relative to
control mice (four injections of 100 ml saline each, every 2–3 days,
n = 3) was evident during the first 4 days after spheroid implanta-
tion, but there was no observable effect on tumour development in
the 3rd week of tumour growth (days 14–18) (Figure 2). For mice
that were injected with a total amount of 0.6 ml wound fluid (six
injections of 100 ml WF each, every 2–3 days, n = 4), there was a
40% increase in growth rate (reduced doubling time) relative to
control mice (six injections of 100 ml saline each, every 2–3 days,
n = 4) observable in the 3rd week (days 14–18) (Figure 2). Mice
injected with a higher dose of WF, i.e. a total amount of 2.4 ml
(eight injections of 300 ml WF, n = 2), showed a significant effect
relative to control mice (eight injections of 300 ml PBS, n = 2, or
300 ml pig plasma, n = 2) through the entire experiment (3 weeks).
Tumour doubling time in WF-treated mice was 6.7 times faster
than control saline or plasma-treated mice on days 14–18
(Figure 2), and tumour volume measured by MRI was fourfold
larger. The maximal volume of WF (2.4 ml) is the amount of WF
released during 1 day from a 2.5 cm2 partial thickness excisional
wound in our experimental wound model in pig. These experi-
ments suggest that the duration and dose of cumulative exposure
to wound-derived factors affects the degree of tumour stimulation.
Wound fluid is angiogenic
The angiogenic capacity of WF was assayed in vivo by MRI.
Agarose beads containing PBS, b-FGF or WF derived 1 day after
injury were implanted subcutaneously in nude mice as reported
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Figure 2 The effect of wound fluid derived from pig on the progression of
C6 glioma tumours in nude mice. Tumour volume was determined every
2–3 days by gradient echo MRI from two orthogonal sets of multislice images
covering the entire tumour (Bruker Biospec spectrometer, 4.7 T; TE = 20 ms,
TR = 100 ms, 0.11 mm in plane resolution; 0.5–0.6 mm slice thickness).
Wound fluid reduced tumour doubling time for C6 glioma tumours in vivo in a
dose-dependent manner on the 3rd week after implantation. WF derived from
injured pigs (days 1–2) was injected into the mice subcutaneously, close to
the implanted spheroid, every 2–3 days. Control animals were injected with
saline or pig plasma
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Figure 3 WF promotes neovascularization in vivo in beads implanted
subcutaneously in nude mice. Agarose beads containing the various
materials were implanted as described in Materials and methods. The
angiogenic potential of WF in vivo is demonstrated quantitatively by MRI. The
apparent vessel density (AVDMRI) was determined from the degree of signal
loss in gradient echo MRI, as described previously (Abramovitch et al, 1995,
1998a; Schiffenbauer et al, 1997). Neovascularization around the beads was
quantitatively evaluated by subtraction of the AVDMRI measured on day 1 from
the one measured on day 4 after implantation (s sAVDMRI). PBS, as a negative
control, did not induce neovascularization around the bead (n = 8), whereas
bFGF, as a positive control, caused significant neovascularization around the
beads (n = 3 and n = 7 for 0.5 and 5 mg bFGF respectively). In comparison,
wound fluid (WF; 5 ml) from the first 3 days after injury induced significant
neovascularization around the beads (n =6 )
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Figure 4 Wound fluid increases DNA synthesis in endothelial cells. The
angiogenic potential of wound fluid in vitro was tested by [3H]thymidine
incorporation into brain bovine capillary endothelial cells (BBCE) as
described in Materials and methods. The angiogenic capacity of WF was
maximal with WF derived 1 day after injury, and decreased slowly during the
wound healing process1396 R Abramovitch et al
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previously (Abramovitch et al, 1995, 199 8a). PBS, a negative
control, did not cause neovascularization around the bead  (ssAVD =
0.08 ±0.06; n=8), whereas b-FG F, a known angiogenic growth
factor, showed dose-dependent increase in the  AVD (n=7) (Figure
3). WF derived from injured pigs during the first 3 days after
injury (fourfold concentrated) showed significant neovasculariza-
tion around the beads  (DAVD = 0.32 ±0.14; n=6), which was
comparable to that observed for 0. 5mg b-FGF  (DAVD = 0.3 ±0.11;
n=3) and less than that of  5mg b-FGF  (DAVD = 0.54 ±0.2; n=7)
(Figure 3). The specificity of the e ffect of pig-derived WF was
evaluated by comparison with pig plasma. In contrast to W F,
implantation of an agarose bead containing pig plasma  (n=4) did
not cause neovascularization around the bead.
In accord with the angiogenic capacity of WF in vivo, WF was
mitogenic to endothelial cells in vitro (Figure 4). WF derived 1 day
after pig injury showed the maximal enhancement of DNA
synthesis ([3H]thymidine incorporation) in bovine endothelial
cells: 2.6-fold increase relative to control cells (Figure 4). This
effect slowly decreased to twofold for WF derived 4 days after
injury.
Wound fluid enhances growth of C6 glioma in vitro
The stimulatory e ffect of WF on the rate of tumour growth
suggests that, in addition to its angiogenic activit y, WF possibly
also exerts a direct e ffect on the rate of tumour cell proliferation.
To identify possible growth factors in WF which promote prolifer-
ation of C6 glioma cells, we studied the direct e ffect of growth
factors known to be present in W F. Basic-FG F, HB-EGF and
PDGF enhanced DNA synthesis in C6 glioma cells, as measured
by thymidine incorporation, in monolayer cell culture (Figure 5A).
Basic-FGF increased DNA synthesis by approximately 1.9-fold
above control. The maximal e ffect was obtained at a concentration
of 1ng ml–1. HB-EGF increased DNA synthesis by 1.95-fold over
negative control, the maximal e ffect being obtained by 3. 3ng ml –1.
PDGF increased DNA synthesis by 1.74-fold above control and
the maximal e ffect was obtained by 3. 3ng ml –1.
The e ffect of these growth factors on the growth of C6 glioma in
three-dimensional spheroid culture was also studied (Figure 5B).
Spheroid growth was significantly stimulated by  1ng ml –1 of
PDGF, EGF and HB-EGF (2.21- to 2.36-fold increased volume in
4 days) compared with control (1.49-fold increased volume)
(Figure 5B). Basic-FGF had a, relativel y, smaller e ffect on
spheroid growth (1.86-fold).
In view of the direct mitogenic activity of PDG F, EGF, HB-EGF
and bFG F, we checked the e ffect of WF on C6 glioma cells. As
expected, WF was indeed directly mitogenic to the C6 glioma
tumour cells (Figure 6A). WF derived from the first 3 days after
injury enhanced DNA synthesis in C6 glioma cells in a dose-
dependent manne r. WF from days 1–2 after injury increased DNA
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Figure 5 Growth factors associated with wound repair are mitogenic to C6
glioma. The mitogenic e ffect of growth factors was determined in vitro.
(A) Basic-FG F, HB-EGF and PDGF, growth factors present in wound fluid
during days 1–2, enhanced DNA synthesis in C6 glioma cells.  (B ) Effect of
growth factors on spheroid growth. PDG F, EGF and HB-EGF at  1ng ml –1
significantly enhanced C6 glioma spheroid growth in vitro. Spheroids were
cultured individually on agar as described in Materials and methods. For
each spheroid, the gain in volume after 4 days in culture was calculated (four
spheroids per treatment)
Figure 6 WF is mitogenic to C6 glioma cells.  (A) The mitogenic activity
of WF on C6 glioma cells in vitro was determined by [3H]thymidine
incorporation. WF derived from the first 3 days after injury enhanced DNA
synthesis in a dose-dependent manne r. (B ) HB-EGF and PDGF are the main
mitogens present in WF for C6 glioma cells. Neutralizing antibodies against
either PDGF-BB or against HB-EGF blocked most of the enhancing e ffect of
wound fluid derived 2 days after pig injur y. Pig plasma had no e ffect on DNA
synthesis in C6 glioma cellssynthesis by approximately 2.4-fold above control. WF derived
3 days after injury increased DNA synthesis by twofold. WF was
more mitogenic to C6 glioma than FCS. Pig plasma (10%), in
contrast, had no effect on thymidine incorporation in C6 glioma
cells (Figure 6B).
With the demonstration that growth factors known to be present
in WF can stimulate tumour cell proliferation, it was of interest to
evaluate their role in the mitogenicity of WF for C6 glioma cells.
This was carried out by antagonizing their activity in WF with
neutralizing antibodies. Neutralizing antibodies against either
PDGF-BB or HB-EGF blocked most of the mitogenic activity of
WF derived 2 days after pig injury for C6 glioma in vitro (Figure
6B). WF derived 2 days after pig injury increased DNA synthesis
in C6 glioma cells fourfold above control. Neutralizing antibodies
against HB-EGF suppressed 95% of the mitogenic effect of WF
and neutralizing antibodies against PDGF-BB suppressed 80% of
the mitogenic effect of WF. Thus, a significant contribution to the
direct mitogenic activity of WF on the tumour cells can be attrib-
uted to these two growth factors. In contrast to WF, pig plasma had
no effect on DNA synthesis in C6 glioma cells (Figure 6B).
DISCUSSION
The increased probability of recurrence and accelerated tumour
growth in the location of tissue injury are common clinical
complications associated with the invasive procedures frequently
used in cancer therapy. Understanding the fundamental principles
that are involved may provide a way to possibly reduce the
incidence and extent of tumour induction resulting from treat-
ment. We have previously demonstrated that MRI can be used to
follow primary tumour angiogenesis in vivo in a model system of
an implanted multicellular spheroid (Abramovitch et al, 1995), as
well as for monitoring the induction of spheroid neovasculari-
zation by proximal injury (Abramovitch et al, 1998a). In the study
reported here, we applied quantitative MRI to measure the angio-
genic properties of wound fluid as well as the stimulatory effect of
wound fluid on the progression of implanted C6 glioma spheroids
in vivo.
The phenomenon of tumour growth enhancement by injury was
reproduced by injecting wound fluid (derived from injured pigs
1–2 days after wound formation) to tumour-bearing mice. Wound
fluid stimulated DNA synthesis in endothelial cells, and accord-
ingly increased vascularization in mouse skin by implanted
agarose beads containing wound fluid. In addition, wound fluid
showed direct mitogenic activity on C6 glioma cells. Thus, this
approach made it possible to identify the growth factors which are
known to participate in wound healing for their role and impor-
tance in the enhancement of tumour proliferation and vasculariza-
tion resulting from injury. HB-EGF is a well-characterized 22-kDa
glycoprotein that binds the EGF receptor with high affinity and is
mitogenic for fibroblasts, smooth muscle cells and epithelial cells
(Higashiyama et al, 1991; Marikovsky et al, 1993). Both HB-EGF
and PDGF were previously shown to be present in wound fluid
(Marikovsky et al, 1993). Moreover, HB-EGF was shown to be
the most prominent heparin-binding mitogen for fibroblasts
(Marikovsky et al, 1993) and for epidermal keratinocytes
(Marikovsky et al, 1996) during wound repair. Recently, we
showed that HB-EGF is angiogenic in vivo, an activity which was
attributed to expression and secretion of VEGF by HB-EGF-stim-
ulated vascular smooth muscle cells (Abramovitch et al, 1998b).
In the study presented here, HB-EGF and PDGF were found to
be the major mitogens for C6 glioma cells present in wound fluid.
We suggest, therefore, that HB-EGF and PDGF are likely candi-
dates for mediating the direct stimulatory effect of wounds on
tumour progression. The fact that neutralization of either HB-EGF
or PDGF inhibited almost all the induced mitogenic effect of
wound fluid on C6 cells is in accord with the findings of a syner-
gistic relation between these two growth factors (M Marikovsky
and M Klagsbrun, unpublished data). A similar induction of prolif-
eration of breast and ovarian cancer cells was recently reported for
HB-EGF released in tumours by infiltrating T-cells (Peoples et al,
1995). In addition, it was shown previously that EGF, PDGF-BB
and other growth factors affect glioma spheroids growth, migra-
tion and invasion (Pedersen et al, 1994). The important effect of
PDGF is reinforced because it was shown that high-grade primary
gliomas express increased levels of PDGF receptors, and the pres-
ence of PDGF receptors appears to correlate with tumour progres-
sion (Strawn et al, 1994). By using dominant negative PDGF-b
receptors, growth of C6 glioma could be inhibited both in vitro and
in vivo. Glioma progression has also been correlated with amplifi-
cation of the EGF receptor gene (Libermann et al, 1985).
The study reported here suggests that specific inhibition of the
key growth factors in wound fluid could possibly be used to
protect cancer patients undergoing surgical intervention from the
tumour stimulatory effects of injury. However, the effect of
neutralizing the activity of these growth factors, known to be
important in wound healing, must first be carefully evaluated.
Furthermore, the specific repertoire of dominant growth factors
could be tumour specific and might be different for rat and
human tumours, as reported previously for glioma cells lines
(Pollack et al, 1991).
In summary, we demonstrate here that growth factors released in
injury sites are directly mitogenic to tumour cells, leading to accel-
erated tumour growth. For C6 glioma cells, the major mitogenic
activity was attributed to HB-EGF and PDGF. In addition, wound
fluid contributes a significant angiogenic activity and thus could
enhance the angiogenic switch of avascular, dormant microtu-
mours. Appropriate inhibition of these stimulatory pathways may
improve the recovery from surgery and prognosis in cancer
patients.
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